Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 4/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | CTSV | O60911 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22368496 | 1.00 | KCNA5 (0.37) | KCNA5DHFRHSD11B1CHRM2CHRM3 | |
| SCHEMBL20009179 | 0.86 | KCNA5 (0.37) | KCNA5DHFRCHRM2CHRM3ALDH1A1 | |
| SCHEMBL22368502 | 0.86 | KCNA5 (0.37) | KCNA5DHFRCHRM2CHRM3ALDH1A1 | |
| SCHEMBL22368509 | 0.83 | KCNA5 (0.35) | KCNA5DHFRALDH1A1MEN1KMT2A | |
| SCHEMBL19990609 | 0.83 | KCNA5 (0.35) | KCNA5DHFRALDH1A1MEN1KMT2A | |
| SCHEMBL20009186 | 0.82 | FKBP1A (0.38) | KCNA5DHFRALDH1A1MEN1KMT2A | |
| SCHEMBL22368497 | 0.81 | ALOX15 (0.35) | KCNA5DHFR | |
| SCHEMBL19990666 | 0.81 | ALOX15 (0.35) | KCNA5DHFR | |
| SCHEMBL19990691 | 0.80 | KCNA5 (0.35) | KCNA5DHFRALDH1A1KMT2ACTSL | |
| SCHEMBL22368484 | 0.80 | KCNA5 (0.35) | KCNA5DHFRALDH1A1KMT2ACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3698796-B1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | NOVARTIS AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3698796-B1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | NOVARTIS AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3698796-A1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | Novartis AG (CH) | 2020-08-26 | — | — | EP | disclosed |
| EP-3698796-A1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | Novartis AG (CH) | 2020-08-26 | — | — | EP | disclosed |
| EP-3519419-B1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2020-05-27 | — | — | EP | disclosed |
| US-10597396-B2 | Beta-lactamase inhibitors | NOVARTIS AG (CH) | 2020-03-24 | — | — | US | disclosed |
| US-20190177324-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2019-06-13 | — | — | US | disclosed |
| US-20190177324-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2019-06-13 | — | — | US | disclosed |
| US-10065957-B2 | Beta-lactamase inhibitors | NOVARTIS AG (CH) | 2018-09-04 | — | — | US | disclosed |
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-03-29 | — | — | US | disclosed |
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-03-29 | — | — | US | disclosed |
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177324-A1 | BETA-LACTAMASE INHIBITORS | MGAM, LCT, GAA | KCNA5 2796/4885DHFR 516/4885HSD11B1 312/4885 |
| US-10597396-B2 | Beta-lactamase inhibitors | MGAM, LCT, GAA | KCNA5 2796/4885DHFR 516/4885HSD11B1 312/4885 |
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | MGAM, LCT, GAA | KCNA5 2796/4885DHFR 516/4885HSD11B1 312/4885 |
| US-10065957-B2 | Beta-lactamase inhibitors | MGAM, LCT, GAA | KCNA5 2796/4885DHFR 516/4885HSD11B1 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.